Repligen (NASDAQ:RGEN - Get Free Report) issued its earnings results on Thursday. The biotechnology company reported $0.44 EPS for the quarter, topping analysts' consensus estimates of $0.41 by $0.03, Zacks reports. The business had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. Repligen updated its FY 2025 guidance to 1.670-1.760 EPS.
Repligen Stock Performance
Shares of NASDAQ RGEN traded down $3.68 during midday trading on Friday, reaching $158.99. The company had a trading volume of 795,356 shares, compared to its average volume of 609,046. The business's 50-day simple moving average is $155.22 and its 200 day simple moving average is $148.79. The stock has a market cap of $8.91 billion, a P/E ratio of -429.69, a P/E/G ratio of 4.23 and a beta of 0.99. Repligen has a 1 year low of $113.50 and a 1 year high of $203.13. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.
Wall Street Analyst Weigh In
A number of equities analysts have recently issued reports on the stock. TD Cowen assumed coverage on shares of Repligen in a research note on Monday, February 10th. They set a "buy" rating and a $200.00 price objective on the stock. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a "hold" rating and a $165.00 price objective on the stock. Canaccord Genuity Group increased their price objective on shares of Repligen from $165.00 to $170.00 and gave the company a "hold" rating in a research note on Friday. Wolfe Research assumed coverage on shares of Repligen in a research note on Thursday, November 14th. They set a "peer perform" rating on the stock. Finally, HC Wainwright reiterated a "buy" rating and set a $180.00 price objective on shares of Repligen in a research note on Friday. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, Repligen currently has a consensus rating of "Moderate Buy" and a consensus target price of $183.36.
Get Our Latest Research Report on RGEN
About Repligen
(
Get Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
See Also
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
